RxDoctor Payments Data

Angel Flores, MD

Cardiovascular Disease · Meadville, PANPI 1245236512

Payments from drug & device makers

$193,102in general payments, 2019–2025

Across 800 payments — averaging $241.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$98K
  • E.r. Squibb & Sons, L.L.C.$34K
  • Amarin Pharma, Inc.$19K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15K
  • Regeneron$8K
  • Amgen$3K
  • plus $17K from 38 others

What the payments were for

  • Consulting fees$10,4935%
  • Speaking & faculty fees$150,13278%
  • Travel & lodging$7,4304%
  • Food & beverage$24,71113%
  • Education$3370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$193,102 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$77,655
Medicare patients
685
Services billed
1,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis20$456,436
CamzyosMavacamten45$370,097
XareltoRivaroxaban328$285,552
EliquisApixaban252$207,072
EntrestoSacubitril/Valsartan117$115,112
JardianceEmpagliflozin114$110,556
OzempicSemaglutide51$52,878
Repatha SureclickEvolocumab72$39,823
FarxigaDapagliflozin Propanediol37$39,632
MultaqDronedarone Hcl17$18,607
Praluent PenAlirocumab30$14,732
Ranolazine ErRanolazine161$14,172
VascepaIcosapent Ethyl22$10,566
BrilintaTicagrelor14$7,625
Ezetimibe169$4,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$497$663,508272 claims
E.r. Squibb & Sons, L.L.C.Camzyos$34,118$370,09745 claims
Johnson & JohnsonXarelto$97,614$285,552328 claims
NovartisEntresto$1,314$115,112117 claims
Boehringer IngelheimJardiance$839$110,556114 claims
Novo NordiskOzempic$667$52,87851 claims
AstraZenecaFarxiga, Brilinta$1,536$47,25751 claims
Sanofi-aventis U.S. LLCMultaq$185$18,60717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Meadville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →